Twist bioscience and centogene launch three panels to advance rare disease and hereditary cancer research and support diagnostics

South san francisco, calif. & cambridge, mass. & rostock, germany & berlin--( business wire )--twist bioscience corporation (nasdaq: twst), a company enabling customers to succeed through its offering of high-quality synthetic dna using its silicon platform, and centogene n.v. (nasdaq: cntg), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of three next-generation sequencing (ngs) target enrichment panels to support rare disease and hereditary cancer research and support diagnostics.
CNTG Ratings Summary
CNTG Quant Ranking